

【Therapeutic category】 Other agents relating to blood and body fluids
【Non-proprietary name】 Palovarotene
【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

Current			Revision		
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)			2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)		
2.4 Patients receiving the strong CYP3A inhibitors (itraconazole, preparations containing ritonavir, preparations containing clarithromycin, posaconazole, voriconazole, ensitrelvir fumaric acid, preparations containing cobicistat, ceritinib, preparations containing darunavir ethanolate, lonafarnib)			2.4 Patients receiving the strong CYP3A inhibitors (itraconazole, preparations containing ritonavir, preparations containing clarithromycin, posaconazole, voriconazole, ensitrelvir fumaric acid, preparations containing cobicistat, ceritinib, preparations containing darunavir ethanolate, lonafarnib, <u>tucatinib ethanolate</u>)		
10. INTERACTIONS			10. INTERACTIONS		
10.1 Contraindications for Co-administration (Do not co-administer with the following)			10.1 Contraindications for Co-administration (Do not co-administer with the following)		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Strong CYP3A inhibitors	Blood concentrations	Because this drug	Strong CYP3A inhibitors	Blood concentrations	Because this drug

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Itraconazole Preparations containing ritonavir Preparations containing clarithromycin Posaconazole Voriconazole Ensitrelvir fumaric acid Preparations containing cobicistat Ceritinib Preparations containing darunavir ethanolate, Lonafarnib	of this drug may increase, which may enhance adverse reactions.	is metabolized primarily by CYP3A, inhibition of its metabolism results in increased blood concentrations of this drug.	Itraconazole Preparations containing ritonavir Preparations containing clarithromycin Posaconazole Voriconazole Ensitrelvir fumaric acid Preparations containing cobicistat Ceritinib Preparations containing darunavir ethanolate, Lonafarnib <u>Tucatinib ethanolate</u>	of this drug may increase, which may enhance adverse reactions.	is metabolized primarily by CYP3A, inhibition of its metabolism results in increased blood concentrations of this drug.
---	--	---	--	--	---

N/A: Not Applicable. No corresponding description is included in the current PRECAUTIONS.

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.